You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarteolol
Accession NumberDB00521  (APRD00195)
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. [PubChem]
Structure
Thumb
Synonyms
Carteolol
Carteololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carteolol HydrochlorideSolution / drops10 mg/mLOphthalmicMedsource Pharmaceuticals2000-01-20Not applicableUs
Carteolol HydrochlorideSolution10 mg/mLOphthalmicSandoz Inc.2000-01-05Not applicableUs
Carteolol HydrochlorideSolution / drops10 mg/mLOphthalmicBausch & Lomb Incorporated2000-01-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CartrolNot Available
EndakRottapharm/Madaus
OcupressNovartis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Carteolol Hydrochloride
51781-21-6
Thumb
  • InChI Key: FYBXRCFPOTXTJF-UHFFFAOYNA-N
  • Monoisotopic Mass: 328.155370383
  • Average Mass: 328.834
DBSALT000319
Categories
UNII8NF31401XG
CAS number51781-06-7
WeightAverage: 292.3734
Monoisotopic: 292.178692644
Chemical FormulaC16H24N2O3
InChI KeyLWAFSWPYPHEXKX-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
IUPAC Name
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
Pharmacology
IndicationFor the treatment of intraocular hypertension and chronic open-angle glaucoma
Structured Indications
PharmacodynamicsCarteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Mechanism of actionThe primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-2 adrenergic receptorProteinyes
antagonist
HumanP07550 details
Beta-1 adrenergic receptorProteinyes
partial agonist
HumanP08588 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

SubstrateEnzymesProduct
Carteolol
8-HydroxycarteololDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityThe most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carteolol Action PathwayDrug actionSMP00658
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Carteolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Carteolol.Experimental
AbirateroneThe serum concentration of Carteolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Carteolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Carteolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Carteolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Carteolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideCarteolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Carteolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Carteolol is combined with Acetylcholine.Approved
AcetyldigitoxinCarteolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Carteolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Carteolol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Carteolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Carteolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Carteolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Carteolol is combined with Aliskiren.Approved, Investigational
AlprenololCarteolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Carteolol.Approved
AmbrisentanCarteolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateCarteolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineCarteolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Carteolol is combined with Amiloride.Approved
AminophyllineCarteolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Carteolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Carteolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Carteolol.Approved, Illicit
AmodiaquineThe metabolism of Carteolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Carteolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Carteolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Carteolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Carteolol.Approved
AnvirzelCarteolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Carteolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Carteolol.Approved, Investigational
ArbutamineCarteolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Carteolol is combined with Arecoline.Experimental
ArformoterolCarteolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Carteolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Carteolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Carteolol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Carteolol can be decreased when combined with Artemether.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Carteolol.Approved
AtomoxetineThe metabolism of Carteolol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Carteolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Carteolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Carteolol.Approved, Investigational
BambuterolCarteolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Carteolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Carteolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carteolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Carteolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Carteolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Illicit
BepridilCarteolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantCarteolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carteolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Carteolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Carteolol.Investigational
BimatoprostCarteolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Carteolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Carteolol is combined with Bortezomib.Approved, Investigational
BosentanCarteolol may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Carteolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Carteolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Carteolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Carteolol.Investigational
BucindololCarteolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Carteolol.Approved, Investigational
BupranololCarteolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Carteolol can be decreased when combined with Bupropion.Approved
CabergolineCarteolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantCarteolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Candesartan.Approved
CandoxatrilCarteolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Carteolol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carteolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Carteolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved, Withdrawn
CarvedilolCarteolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Carteolol.Experimental
CelecoxibThe metabolism of Carteolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCarteolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibCarteolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Carteolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Carteolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Carteolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe metabolism of Carteolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideCarteolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carteolol.Approved
CholecalciferolThe metabolism of Carteolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Cilnidipine.Approved
CimetidineThe metabolism of Carteolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Carteolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Carteolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Carteolol can be decreased when combined with Clemastine.Approved
ClenbuterolCarteolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Carteolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Carteolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Carteolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Carteolol.Approved
ClotrimazoleThe metabolism of Carteolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Carteolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Carteolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Carteolol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Carteolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Carteolol.Vet Approved
CrizotinibCarteolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCarteolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Carteolol.Investigational
CyclothiazideCarteolol may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Carteolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Carteolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Carteolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Carteolol can be increased when it is combined with Darunavir.Approved
DebrisoquinCarteolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Carteolol.Approved
DelavirdineThe metabolism of Carteolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Carteolol.Approved
DeserpidineCarteolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Carteolol is combined with Desflurane.Approved
DesipramineThe metabolism of Carteolol can be decreased when combined with Desipramine.Approved
DeslanosideCarteolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Carteolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Carteolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Carteolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Carteolol.Approved
DigitoxinCarteolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Carteolol.Approved
DihydralazineCarteolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Carteolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Carteolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Carteolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinCarteolol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Carteolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Carteolol.Approved
DobutamineCarteolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Carteolol.Approved
DorzolamideCarteolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinCarteolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Carteolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Carteolol.Approved
DroxidopaCarteolol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineCarteolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Carteolol.Investigational
DyphyllineCarteolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Carteolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Carteolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Carteolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Carteolol.Approved
EfonidipineCarteolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Carteolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatCarteolol may increase the hypotensive activities of Enalaprilat.Approved
EphedraCarteolol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Carteolol is combined with EPIBATIDINE.Experimental
EpinephrineCarteolol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Carteolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Carteolol is combined with Eplerenone.Approved
EpoprostenolCarteolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Eprosartan.Approved
Ergoloid mesylateCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineCarteolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Carteolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Carteolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Carteolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Carteolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
EtoperidoneThe serum concentration of Carteolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Carteolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Carteolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Carteolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Carteolol.Approved
FenoldopamCarteolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Carteolol.Approved
FenoterolCarteolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Carteolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Carteolol.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Fimasartan.Approved
FingolimodCarteolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Carteolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Carteolol.Vet Approved
FluoxetineThe metabolism of Carteolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Carteolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Carteolol.Approved, Investigational
FluvoxamineThe metabolism of Carteolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolCarteolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carteolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Carteolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Carteolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Carteolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Carteolol.Approved, Nutraceutical
GlibornurideCarteolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideCarteolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCarteolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCarteolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneCarteolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideCarteolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideCarteolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Carteolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Carteolol.Approved
GuanethidineCarteolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Investigational
HaloperidolThe metabolism of Carteolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Carteolol is combined with Halothane.Approved, Vet Approved
HexamethoniumCarteolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Carteolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Carteolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Carteolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Carteolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Carteolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCarteolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Carteolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Carteolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Carteolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Carteolol.Approved
IloprostIloprost may increase the hypotensive activities of Carteolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Imidapril.Investigational
ImipramineThe metabolism of Carteolol can be decreased when combined with Imipramine.Approved
IndacaterolCarteolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Carteolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Indapamide.Approved
IndenololCarteolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Carteolol can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Carteolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Carteolol.Withdrawn
IndoraminCarteolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkCarteolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Carteolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Carteolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Carteolol.Approved
IsoetarineCarteolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Carteolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Carteolol.Approved, Withdrawn
IsoniazidThe metabolism of Carteolol can be decreased when combined with Isoniazid.Approved
IsoprenalineCarteolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Carteolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Carteolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Carteolol.Approved
IvabradineCarteolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Carteolol.Experimental
KetanserinCarteolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Carteolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Carteolol.Approved
LabetalolCarteolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineCarteolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideCarteolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideCarteolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostCarteolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Carteolol.Approved, Investigational
LercanidipineCarteolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Carteolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Carteolol is combined with Levobupivacaine.Approved
LevodopaCarteolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Carteolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Carteolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Carteolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Carteolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Carteolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Investigational
LopinavirThe metabolism of Carteolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Carteolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Carteolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Carteolol.Approved
LucinactantCarteolol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineThe metabolism of Carteolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Carteolol.Approved, Investigational
MacitentanCarteolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Carteolol.Approved
MalathionMalathion may increase the bradycardic activities of Carteolol.Approved, Investigational
ManidipineCarteolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Carteolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Carteolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Carteolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Carteolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Carteolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Carteolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Carteolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Carteolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Carteolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Carteolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Carteolol is combined with Methacholine.Approved
MethadoneThe metabolism of Carteolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Carteolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Carteolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Carteolol.Approved
MethotrimeprazineThe metabolism of Carteolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carteolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Carteolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Carteolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Carteolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carteolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Carteolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Carteolol is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Carteolol.Approved, Investigational
MetyrosineCarteolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilCarteolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineCarteolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Carteolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Carteolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carteolol.Approved
MirabegronThe metabolism of Carteolol can be decreased when combined with Mirabegron.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Carteolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Carteolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Carteolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Carteolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Carteolol is combined with Morphine.Approved, Investigational
MoxonidineCarteolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Carteolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Carteolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Carteolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Carteolol.Approved
NadololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Carteolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Carteolol.Approved
NaftopidilCarteolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Carteolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Carteolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Carteolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Carteolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Carteolol is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Carteolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Carteolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Carteolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Carteolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Carteolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Carteolol.Approved
NiguldipineCarteolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Carteolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineCarteolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Carteolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Carteolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carteolol.Approved
NitrendipineCarteolol may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Carteolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Carteolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Carteolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carteolol.Approved
NorepinephrineCarteolol may decrease the bronchodilatory activities of Norepinephrine.Approved
ObinutuzumabCarteolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Carteolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Carteolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Carteolol.Approved, Investigational
OlodaterolCarteolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Carteolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Carteolol.Approved
OmapatrilatCarteolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineCarteolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Carteolol.Vet Approved
OuabainCarteolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Carteolol.Approved
OxprenololCarteolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Carteolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Carteolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
PanobinostatThe serum concentration of Carteolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Carteolol.Approved
PargylinePargyline may increase the hypotensive activities of Carteolol.Approved
ParoxetineThe metabolism of Carteolol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideCarteolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Carteolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Carteolol.Approved, Vet Approved
PentoliniumCarteolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Carteolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Carteolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Carteolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Carteolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Carteolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Carteolol.Approved
PhenoxybenzamineCarteolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Carteolol.Withdrawn
PhentolamineCarteolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
PhenylpropanolamineCarteolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Carteolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Carteolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Carteolol.Approved, Investigational
PinacidilCarteolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Carteolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Carteolol is combined with Pipamperone.Approved
PirbuterolCarteolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Carteolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Carteolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Carteolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Carteolol.Withdrawn
PolythiazideCarteolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaCarteolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Carteolol is combined with Pramipexole.Approved, Investigational
PrazosinCarteolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Carteolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Carteolol.Approved, Vet Approved
ProcaterolCarteolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Carteolol.Approved, Vet Approved
PromazineThe metabolism of Carteolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Carteolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Carteolol.Approved
PropafenoneThe serum concentration of Carteolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Carteolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Carteolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Carteolol is combined with Propranolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Carteolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Carteolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Carteolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Carteolol is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Carteolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Carteolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Carteolol.Approved
RanolazineThe metabolism of Carteolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Carteolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Carteolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Carteolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Carteolol.Approved
RescinnamineCarteolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Carteolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Carteolol.Experimental, Investigational
RifampicinThe serum concentration of Carteolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Carteolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineCarteolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Carteolol is combined with Riociguat.Approved
RisperidoneCarteolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineCarteolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Carteolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCarteolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Carteolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Carteolol.Investigational, Withdrawn
RolapitantThe metabolism of Carteolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Carteolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Carteolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Carteolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Carteolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Carteolol.Withdrawn
SalbutamolCarteolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Carteolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
SalmeterolCarteolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Carteolol.Approved
SaprisartanCarteolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Carteolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Carteolol.Approved, Investigational, Vet Approved
SelexipagCarteolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Carteolol.Approved, Investigational
SertralineThe metabolism of Carteolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Carteolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Carteolol.Approved, Investigational
SilodosinCarteolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanCarteolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Carteolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.Approved
SpiraprilCarteolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Carteolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Carteolol.Investigational
StiripentolThe metabolism of Carteolol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Carteolol is combined with Streptokinase.Approved
SufentanilCarteolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Carteolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Carteolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Carteolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Carteolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Carteolol.Approved, Investigational
TamsulosinCarteolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Carteolol is combined with Telmisartan.Approved, Investigational
TemocaprilCarteolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Carteolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Carteolol.Vet Approved
TerazosinCarteolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Carteolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineCarteolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Carteolol.Approved
TerlipressinCarteolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Carteolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineCarteolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Carteolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Carteolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Carteolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Carteolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Carteolol.Approved
TiboloneCarteolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Carteolol can be decreased when combined with Ticlopidine.Approved
TicrynafenCarteolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Carteolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Carteolol.Investigational
TipranavirThe metabolism of Carteolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Carteolol.Approved, Investigational
TolazamideCarteolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineCarteolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideCarteolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Carteolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Carteolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Carteolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Carteolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Carteolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Carteolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Carteolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carteolol.Experimental
TranylcypromineThe metabolism of Carteolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Carteolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Carteolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Carteolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Carteolol.Vet Approved
TrichlormethiazideCarteolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Carteolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Carteolol.Approved, Vet Approved
TrimazosinCarteolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanCarteolol may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Carteolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Carteolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Carteolol.Approved, Investigational
UnoprostoneCarteolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Carteolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Carteolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Carteolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Carteolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Carteolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Carteolol is combined with Verapamil.Approved
VilanterolCarteolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinpocetineCarteolol may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Carteolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Carteolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Carteolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Carteolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Carteolol can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Carteolol.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Tamura,Y., Nakagawa,K., Yoshizaki,S.and Murakami,N.; U.S.Patent 3,910,924; October 7,
1975; assigned to Otsuka Pharmaceutical Co., Ltd.

General References
  1. El-Kamel A, Al-Dosari H, Al-Jenoobi F: Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9. [PubMed:16401594 ]
  2. Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A: Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea. 2005 Mar;24(2):213-20. [PubMed:15725891 ]
  3. Trinquand C, Romanet JP, Nordmann JP, Allaire C: [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. J Fr Ophtalmol. 2003 Feb;26(2):131-6. [PubMed:12660585 ]
External Links
ATC CodesS01ED55S01ED05C07AA15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.5578
Caco-2 permeable-0.6897
P-glycoprotein substrateSubstrate0.9025
P-glycoprotein inhibitor INon-inhibitor0.6539
P-glycoprotein inhibitor IINon-inhibitor0.9197
Renal organic cation transporterNon-inhibitor0.8058
CYP450 2C9 substrateNon-substrate0.7911
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.59
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.8024
CarcinogenicityNon-carcinogens0.9099
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4801 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9902
hERG inhibition (predictor II)Non-inhibitor0.5237
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Bausch and lomb inc
  • Novex pharma
  • Novartis pharmaceuticals corp
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic10 mg/mL
Solution / dropsOphthalmic10 mg/mL
Prices
Unit descriptionCostUnit
Carteolol HCl 1% Solution 15ml Bottle57.82USD bottle
Carteolol HCl 1% Solution 10ml Bottle38.55USD bottle
Carteolol HCl 1% Solution 5ml Bottle22.13USD bottle
Carteolol hcl 1% eye drops3.93USD ml
Cartrol 2.5 mg tablet1.37USD tablet
Cartrol 5 mg tablet1.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.421 mg/mLALOGPS
logP1.05ALOGPS
logP1.42ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)13.41ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity83.14 m3·mol-1ChemAxon
Polarizability32.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroquinolones. These are compounds containing a hydrogenated quinoline bearing a ketone group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinolones and derivatives
Direct ParentHydroquinolones
Alternative Parents
Substituents
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Alkyl aryl ether
  • Benzenoid
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Lactam
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Chidlow G, Melena J, Osborne NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66. [PubMed:10864881 ]
  4. Floreani M, Froldi G, Quintieri L, Varani K, Borea PA, Dorigo MT, Dorigo P: In vitro evidence that carteolol is a nonconventional partial agonist of guinea pig cardiac beta1-adrenoceptors: a comparison with xamoterol. J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95. Epub 2005 Sep 13. [PubMed:16160085 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kudo S, Uchida M, Odomi M: Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol. 1997;52(6):479-85. [PubMed:9342584 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23